NCT03915366CompletedPhase 2/3
Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia
Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia: a Multicenter, Open-label Randomized Controlled Clinical Trial
Source: ClinicalTrials.gov · Last updated 19 Sept 2025
Brief summary (registry, in English)
This trial will evaluate whether empirical treatment against cytomegalovirus and tuberculosis improves survival of HIV-infected infants with severe pneumonia.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 563 (actual)
- First submitted
- 10 Apr 2019
- Start date
- 1 Mar 2020
- Primary completion date
- 31 Jan 2025
- Lead sponsor
- Hospital Universitario 12 de Octubre
- Diseases
- Tuberculosis, HIV
- NCT number
- NCT03915366
- EudraCT number
- 2019-001749-42
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 563
- From 1 Mar 2020 to the primary completion date, 31 Jan 2025
- 13 sites in 11 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient previously treated for TB or currently on treatment for TB
- Documented evidence of close TB exposure (household contact of a patient with documented TB during the lifetime of the child, or currently receiving TB-T)
- Systemic immunosuppressive medications. Steroids will be considered to be immunosuppressing only if \>2 mg/kg of prednisone or equivalent during \>15 days
Other illness
- Active malignancies
- Evidence of condition other than HIV and pneumonia which precludes, to the judgment of the clinical researcher, enrollment in this trial due to risk for the patient. In case of doubt, the Trial Management Team will be contacted to assess eligibility
Lab values
- Pure wheezers defined as a clear clinical improvement after a bronchodilator test (give a challenge of rapid-acting inhaled bronchodilator for up to three times 15-20 minutes apart. Count the breaths and look for chest indrawing again, and then re-classify)
- Hb \<6 g/dL in the screening blood test or in a test done in the last 48 hours. Transfusion is permitted to achieve \>6 g/dL if the patient's state allows it. In case a transfusion is administered, the patient can be enrolled
Other
- Clinical TB (pulmonary or extrapulmonary) diagnosis, defined as the necessity of TB-T prescribed by a physician, at the moment of randomization
- Known bacteriologically confirmed TB case (at least one biological specimen positive by culture or Xpert MTB/RIF) at the moment of randomization
- Less than 2.5 kg of weight
- Neutropenia \<500 /mm3 in the screening blood test or in a test done in the last 48 hours. Repeating the test is allowed to check eligibility
Who the study is looking for
- Age 28 days to 365 days of age
- Pneumonia defined as chest indrawing or fast breathing for age, for infants 28 to 60 days of age ≥60 breaths per minute and for infants 61 to 365 days of age, ≥50 breaths per minute.
- Current hospitalization due to pneumonia with criteria for parenteral antibiotics (1 or more criteria)
- Chest indrawing with HIV infection
- No improvement with oral treatment.
- One or more danger signs according to WHO 5,44,45
- Central cyanosis or saturation of O2 \<90%
- Severe respiratory distress, e.g. grunting or very severe chest indrawing
- Signs of pneumonia with a general danger sign:
- Unable to drink or breastfeed
- Persisting vomiting
- Convulsions in the last 24 hours
- Lethargic or unconscious
- Stridor while calm
- Severe malnutrition
- HIV-confirmed infection (with at least one molecular method: DNA polymerase chain reaction (PCR) or RNA PCR/viral load).
- Informed consent obtained
Age in the registry: 28 days to 365 days · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Programme PACCI. Centre Hospitalier Cocody. Coordinator of this site? Confirm its status | Abidjan | Côte d’Ivoire | Unknown status |
| Fundación para la Investigación Biomédica del Hospital 12 de Octubre Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Université de Bourdeaux Coordinator of this site? Confirm its status | Bourdeaux | France | Unknown status |
| INSERM Coordinator of this site? Confirm its status | Toulouse | France | Unknown status |
| University of Lincoln Coordinator of this site? Confirm its status | Lincoln | United Kingdom | Unknown status |
| PENTA Foundation Coordinator of this site? Confirm its status | Padova | Italy | Unknown status |
| Malawi Liverpool Welcome Trust. Queen Elizabeth Central Hospital College of Medicine Coordinator of this site? Confirm its status | Blantyre | Malawi | Unknown status |
| Cemtro de Investigaçao em Saúde da Manhiça Coordinator of this site? Confirm its status | Manhiça | Mozambique | Unknown status |
| Hospital Central Maputo Coordinator of this site? Confirm its status | Maputo | Mozambique | Unknown status |
| Stichting Katholieke Universiteit Radboudumc Coordinator of this site? Confirm its status | Nijmegen | Netherlands | Unknown status |
| Makerere University - Mulago Hospital Coordinator of this site? Confirm its status | Kampala | Uganda | Unknown status |
| Lusaka Teaching Hospital Coordinator of this site? Confirm its status | Lusaka | Zambia | Unknown status |
| University of Zimbabwe Clinical Research Centre Coordinator of this site? Confirm its status | Harare | Zimbabwe | Unknown status |
Related publications
- Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial.Lancet · 2026 · PMID 42468541
- Pharmacokinetics and pharmacodynamics of valganciclovir in infants with severe HIV-associated pneumonia in Africa: a sub-study of the EMPIRICAL randomised controlled trial.EClinicalMedicine · 2026 · PMID 42016921
This page is information, not medical advice. Discuss any trial with your doctor.